Metrics as of 10/17/2026, 07:38 AM (Berlin time), refresh in progress.
Illumina Stock
Illumina, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Jacob Thaysen
- Employees
- 8,600
- Market cap
- $39.6 B
- IPO
- 28/07/2000
Illumina, Inc. is a healthcare company headquartered in San Diego, US, specializing in the delivery of advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Illumina stock: price history
1D
-2.0%
1W
-5.6%
1M
+14.7%
6M
+95.2%
YTD
+100.2%
1Y
+173.7%
2Y
+82.5%
5Y
-34.1%
10Y
+95.8%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~53% stronger price swings than usual
Illumina stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
3 more assignments (Enabler/Second row) Pro-only.
Illumina is a provider of technologies for sequencing and analysing genetic data. The company distributes specialized instruments as well as the required consumables for research applications and clinical settings. Target audiences include research institutions, universities, medical laboratories, and pharmaceutical and biotechnology companies worldwide. Distribution occurs both directly and through distributors across various regions. The portfolio ranges from cancer diagnostics to reproductive health and includes hardware, maintenance services, as well as licensing models.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
CareDx, IncDescriptionAsk the agents about Illumina
Analyst assessment of Illumina
PRICE TARGET LOW
US$155.00
CONSENSUS
US$241.00
MEDIAN
US$232.50
PRICE TARGET HIGH
US$305.00
1
STRONG BUY
26
BUY
17
HOLD
6
SELL
0
STRONG SELL
50
TOTAL · Buy
As of: 13/10/2026
Illumina stock metrics
P/E
48.53
P/B
13.97
EV/EBITDA
30.18
RETURN ON EQUITY
7.3%
NET MARGIN
17.9%
DEBT/EQUITY
0.89
DIVIDEND YIELD
0.0%
AS OF
28/06/2026
Free float & liquidity
FREE FLOAT
99.7%
FLOAT SHARES
150,483,127
AVG. DAILY VOLUME (30D)
3,705,863
Insider transactions (SEC)
Thaysen Jacob
Meister Keith A.
Ullem Scott B.
Coletti Julie Ann
Coletti Julie Ann
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.0%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Illumina stock
What does Illumina do?
Illumina, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Jacob Thaysen, the company employs around 8,600 people.
The IPO was on 28/07/2000; the stock trades on NASDAQ under the ticker ILMN.
What do analysts say about Illumina stock?
50 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$241.00, ranging from US$155.00 to US$305.00, with a median of US$232.50.
This is an external assessment, not a statement by Market Jury.
When does Illumina report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 53% stronger than usual.
Does Illumina pay a dividend?
No, Illumina currently does not pay a dividend.
Which stocks are comparable to Illumina?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, IDEXX Laboratories and Mettler-Toledo International.
How can I get Illumina stock analyzed?
Clicking "Analyze stock" lets five strategies assess Illumina against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.